CAJ | 학술논문

利妥昔单抗注射液作为最早应用于临床的CD20单抗类药物，广泛用于CD20阳性的淋巴瘤和一些自身免疫性疾病的治疗。近年的研究发现，该药除了可以清除恶性B细胞，减少自身抗体，对T细胞的功能也有一定影响，并在此基础上进一步拓展了该药的应用范围。该文概述了近年来利妥昔单抗注射液对不同免疫细胞作用机制的研究进展以及关于该药临床应用的一些最新报道，同时也对未来的研究方向进行了探讨。
리타석단항주사액작위최조응용우림상적CD20단항류약물，엄범용우CD20양성적림파류화일사자신면역성질병적치료。근년적연구발현，해약제료가이청제악성B세포，감소자신항체，대T세포적공능야유일정영향，병재차기출상진일보탁전료해약적응용범위。해문개술료근년래리타석단항주사액대불동면역세포작용궤제적연구진전이급관우해약림상응용적일사최신보도，동시야대미래적연구방향진행료탐토。
Rituximab,as the earliest anti-CD20 monoclonal antibody applied in humans,has been widely used for treating CD20 +lymphomas and some autoimmune diseases.Recent researches have found that ritux-imab not only eradicates malignant B-cells and decreases autoantibody production , but also impairs T cell function,therefore, the application range of rituximab has been expanded.Here is to make a review of research progress on the action mechanism of rituximab in different immune cells as well as the latest reports of its clinical application in recent years,in order to explore the research direction in future.